Phase I, Open-Label, Two Parts Study in Chinese Patients With Advanced NSCLC Who Have Progressed Following Prior Therapy With an EGFR Tyrosine Kinase Inhibitor Agent

Trial Profile

Phase I, Open-Label, Two Parts Study in Chinese Patients With Advanced NSCLC Who Have Progressed Following Prior Therapy With an EGFR Tyrosine Kinase Inhibitor Agent

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Acronyms AURAChinaPK
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.
    • 01 Mar 2016 Planned End Date changed from 1 Nov 2016 to 1 Oct 2016 as per ClinicalTrials.gov record.
    • 20 Nov 2015 Planned End Date changed from 1 Jan 2017 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top